Background: Anti-inflammatory drugs and DMARDs, especially methotrexate, have dramatically
improved the outlook of RA patient. However, in some patients the treatment effect is still
not satisfactory and needs to change therapeutic regimen in time. So, timely prediction of patient
treatment effect is particularly important.
Methods: miRNAs are a large family of highly conserved noncoding genes and some of them become
potential biomarker of disease diagnosis. Circulating miR-10a was detected by qRT-PCR. Receiver
operating characteristic (ROC)curve analyses were performed for circulating miR-10a in RA diagnosis
and predictor of therapy effectiveness in RA patients treated with methotrexate.
Results and Conclusion: In the present study, we found that the circulating miR-10a was significantly
decreased in RA patients compared to osteoarthritic patients and healthy people. Importantly, circulating
miR-10a was up-regulated in RA patients treated with MTX. Moreover, we identified circulating
miR-10a that may serve as a biomarker of RA diagnosis and predictor of therapy effectiveness in
rheumatoid arthritis patients treated with methotrexate.